Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs AMS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRAL Captures Overall Composite Edge (54.5 HOLD vs 33.8 SELL), While AMS Leads 4–2 on Growth & Valuation Pillars

GRAL Overall Winner 6-Pillar Tally: GRAL 2 – 4 AMS Matrix Metrics: GRAL 5 – 5 AMS

As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (54.5/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while AMS wins 4–2 across the 6-pillar growth and valuation breakdown. GRAL trades at $105.60 (1.1x Forward P/E, -332.0% operating margin) versus AMS at $1.07 (44.6x Forward P/E, -7.4% operating margin).

  • Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. AMS 33.8/100 SELL) and 3.09β · 99% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile AMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs AMS
GRAL NASDAQ Head-to-Head Winner
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
TTM Revenue $30M
Forward P/E 44.6x
Beta / 30D Vol 0.18β · 46% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $1.21 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (GRAL 2 – 4 AMS)

Columns: Metric · GRAL · AMS
1. Valuation Multiples GRAL
Forward P/E 1.1x 44.6x
Trailing P/E 1.1x 44.6x
PEG Ratio N/M N/M
EV / Revenue 31.6x 0.8x
2. Growth & Scale GRAL
Revenue Growth (YoY) +3.7% +19.2%
Earnings Growth (YoY) +0.0% -38.1%
TTM Revenue (USD) $167M $30M
Market Cap $5.2B $7.2M
3. Profitability & Quality AMS
Gross Margin 46.7% 34.8%
Operating Margin -332.0% -7.4%
Net Profit Margin -243.8% -5.8%
Return on Equity (ROE) -17.3% -12.1%
4. Balance Sheet & Cash Flow AMS
Cash Generation (TTM) -$312M -$916,000
Cash Flow Margin N/A -3.0%
Net Cash / Leverage $57M Net Debt (0.03x D/E) $17M Net Debt (0.95x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AMS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 93.0% (53rd %ile) N/A (N/A)
Put/Call OI Skew 0.81x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AMS
OpEx & R&D Intensity N/A 42.2% of Rev ($13M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (5) vs AMS (5)
Institutional Metric GRAL AMS Criterion Row Edge
Market Capitalization
Scale
$5.2B $7.2M Larger Scale GRAL
Trailing P/E Ratio
Valuation
1.1x 44.6x Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x 44.6x Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% +19.2% Higher Growth AMS
Operating Margin (TTM)
Profitability
-332.0% -7.4% Higher Margin AMS
Net Profit Margin
Profitability
-243.8% -5.8% Higher Margin AMS
Return on Equity (ROE)
Capital Efficiency
-17.3% -12.1% Higher ROE AMS
52-Week Range Position
Momentum
51% ($42–$166) 6% ($1–$2) Stronger Trend GRAL
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol 0.18β · 46% Vol Lower Realized Risk AMS
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 33.8 / 100 (SELL) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$167M $30M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 34.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) -$916,000 ($17M Net Debt (0.95x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRAL +6.05 pp
GRAL: -10.36% · AMS: -16.41%
3M Horizon GRAL +81.93 pp
GRAL: +50.96% · AMS: -30.97%
6M Horizon GRAL +104.24 pp
GRAL: +77.03% · AMS: -27.21%
1Y Horizon GRAL +79.15 pp
GRAL: +26.92% · AMS: -52.23%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GRAL Revenue AMS Revenue GRAL Op. Margin AMS Op. Margin Margin Leader
FY2018 N/A $20M N/A 9.4% AMS
FY2019 N/A $20M N/A 7.5% AMS
FY2020 N/A $20M N/A -53.1% AMS
FY2021 N/A $20M N/A 7.7% AMS
FY2022 N/A $20M N/A 12.3% AMS
FY2023 $90M $20M -1627.6% 1.3% AMS
FY2024 $130M $30M -1743.0% -9.9% AMS
FY2025 $150M $30M -382.0% -12.8% AMS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.2M market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($13M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries ASE Technology Holding Amkor Technology

Investor FAQ GRAL vs AMS Key Questions & Quantitative Answers

As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (54.5/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while AMS wins 4–2 across the 6-pillar growth and valuation breakdown. GRAL trades at $105.60 (1.1x Forward P/E, -332.0% operating margin) versus AMS at $1.07 (44.6x Forward P/E, -7.4% operating margin). Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. AMS 33.8/100 SELL) and 3.09β · 99% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile AMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GRAL leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with AMS at +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GRAL cumulative revenue shifted +66.7% while AMS shifted +50.0%. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 42.2% of Rev ($13M) (0 disclosures) for AMS.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus AMS (-12.1% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.